Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

PharmaEngine's Pancreatic Cancer Drug Seeks Approval in Europe

publication date: May 4, 2015
PharmaEngine of Taiwan announced that its licensing partner, Merrimack Pharma of Boston, and its sublicensing partner, Baxter International, have applied for European marketing approval of MM-398, a liposome-encased form of irinotecan. The drug is indicated to treat metastatic pancreatic cancer in patients previously treated with gemcitabine. PharmaEngine retains rights to the drug in Taiwan, but out-licensed the global rights (ex-Taiwan) to Merrimack in 2011 for $10 million upfront and $210 million in milestones, plus royalties. More details....

Stock Symbols: (TWO:4162) (NSDQ: MACK) (NYSE: BAX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital